The protein corona hampers the transcytosis of transferrin-modified nanoparticles through blood–brain barrier and attenuates their targeting ability to brain tumor

Xiao, Wei; Wang, Yazhen; Zhang, Huilin; Liu, Yuwei; Xie, Rou; He, Xueqin; Zhou, Yang; Liang, Luqing; Gao, Huile

doi:10.1016/j.biomaterials.2021.120888

Cited by 118 publications

(75 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50 While functionalization of non-viral vectors with various non-specific and specific BBB-targeting moetities has shown promising results in improving transcytosis, recent literature has demonstrated that adsorption of endogenous proteins ( protein corona) can affect the effectiveness of these targeting moieties and the ability of non-viral vectors to undergo transcytosis. [51][52][53] In two such studies, functionalization of non-viral vectors with PEG spaces and Transferrin ligands resulted in significantly higher cellular uptake in BBB related cells in the absence of serum but this effect was lost in the presence of serum. This demonstrated that the absorption of serum proteins and formation of a protein corona mitigated the ability for cellular receptors to recognize grafted targeting moieties in vitro.…”

Section: Brain Transcytosismentioning

confidence: 99%

Overcoming barriers in non-viral gene delivery for neurological applications

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Brain Transcytosismentioning

confidence: 99%

Overcoming barriers in non-viral gene delivery for neurological applications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Therefore, Wang et al added FA and TMZ to GO and the system showed a pHdependent response as well as sustained release properties after reaching the glioma area, effectively reducing the drug dose and prolonging its duration of action in vitro (120). Transferrin (Tf)mediated transport has been proven to cross the blood-brain barrier, which makes Tf a potential molecular therapeutic target in the treatment in the treatment of glioma (121). In addition, Tf receptors are overexpressed on the surface of glioma cells (122).…”

Section: Graphene Oxide Nanocarriers As Drug Delivery Systemsmentioning

confidence: 99%

The Role of Graphene Oxide Nanocarriers in Treating Gliomas

Wang

Guo

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Gliomas are the most common primary malignant tumors of the central nervous system, and their conventional treatment involves maximal safe surgical resection combined with radiotherapy and temozolomide chemotherapy; however, this treatment does not meet the requirements of patients in terms of survival and quality of life. Graphene oxide (GO) has excellent physical and chemical properties and plays an important role in the treatment of gliomas mainly through four applications, viz. direct killing, drug delivery, immunotherapy, and phototherapy. This article reviews research on GO nanocarriers in the treatment of gliomas in recent years and also highlights new ideas for the treatment of these tumors.

show abstract

“…It was anticipated that the modification of NPs with targeting ligands will enhance the delivery of therapeutics to targeted or diseased tissues. However, the formation of protein corona on NP exposure to the bloodstream may highly alter the binding of the targeting ligand to its receptor (Xiao et al, 2021).…”

Section: Formulation Outcomes Referencesmentioning

confidence: 99%

An Insight to Brain Targeting Utilizing Polymeric Nanoparticles: Effective Treatment Modalities for Neurological Disorders and Brain Tumor

Annu

Ali

Qamar

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The delivery of therapeutic molecules to the brain remains an unsolved problem to the researchers due to the existence of the blood–brain barrier (BBB), which halts the entry of unwanted substances to the brain. Central nervous system (CNS) disorders, mainly Parkinson’s disease, Alzheimer’s disease, schizophrenia, brain tumors, and stroke, are highly prevalent globally and are a growing concern for researchers due to restricting the delivery of pharmaceutical drugs to the brain. So effective treatment modalities are essential to combat the growing epidemic of CNS diseases. Recently, the growing attention in the field of nanotechnology has gained the faith of researchers for the delivery of therapeutics to the brain by targeting them to the specific target site. Polymeric nanoparticles (PNPs) emerge out to be an instrumental approach in drug targeting to the brain by overcoming the physiological barrier, biomedical barrier, and BBB. Preclinical discovery has shown the tremendous potential and versatility of PNPs in encapsulating several drugs and their targeting to the deepest regions of the brain, thus improving therapeutic intervention of CNS disorders. The current review will summarize advances in the development of PNPs for targeting therapeutics to the brain and the functional and molecular effects obtained in the preclinical model of most common CNS diseases. The advancement of PNPs in clinical practice and their prospect in brain targeting will also be discussed briefly.

show abstract

The protein corona hampers the transcytosis of transferrin-modified nanoparticles through blood–brain barrier and attenuates their targeting ability to brain tumor

Cited by 118 publications

References 66 publications

Overcoming barriers in non-viral gene delivery for neurological applications

Overcoming barriers in non-viral gene delivery for neurological applications

The Role of Graphene Oxide Nanocarriers in Treating Gliomas

An Insight to Brain Targeting Utilizing Polymeric Nanoparticles: Effective Treatment Modalities for Neurological Disorders and Brain Tumor

Contact Info

Product

Resources

About